Federico Grossi - 14 Jan 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: CHIEF MEDICAL OFFICER
Signature: /s/ David Watson, attorney-in-fact for Dr. Federico Grossi
Issuer symbol: APLS
Transactions as of: 14 Jan 2022
Net transactions value: -$556
Form type: 4
Filing time: 19 Jan 2022, 19:03:55 UTC
Previous filing: 14 Jan 2022
Next filing: 25 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$14,654	+3,400	+4.5%	$4.31^*	78,915	14 Jan 2022	Direct
transaction	APLS	Common Stock	Sale	$15,210	-375	-0.48%	$40.56	78,540	14 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-3,400	-4.9%	$0.000000	65,423	14 Jan 2022	Common Stock	3,400	$4.31	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This is a scheduled sale from 10B5-1 trading plan.
F2	This stock option was granted on 08/21/2017 and is fully vested.